NANTES, FRANCE--(MARKET WIRE)--Aug 30, 2007 -- VIVALIS (Euronext Paris: VLS), a biopharmaceutical company specialised in the development and marketing of technologies for manufacturing vaccines and products for the prevention and treatment of viral diseases, today announces its results for the 1st half of 2007, ended on June 30, 2007.
